Alcon has earned CE mark approval for its Clarion Vivity intraocular lens (IOL). The company said it will begin commercial rollout in Europe from early Q2 2025.

According to the company, Clareon is a material with one of the lowest levels of haze and glistenings compared to leading competitor IOLs. It provides sharp, crisp vision with a proprietary edge to help reduce glare and posterior capsular opacification. Its Stableforce haptics also offer axial and rotational stability.

Clareon Vivity leverages a wavefront-shaping optical principle, trademarked as X-Wave technology. It uses proprietary transition elements to create advanced and delayed wavefronts for a continuously extended focal range.

When compared to an aspheric monofocal, Alcon said Clareon Vivity reduce spectacle dependence, offered comparable distance vision, and improved intermediate and near vision while maintaining overall mesopic contrast sensitivity.

Dr. Mercè Guarro, CEO Instituto de Oftalmologia Médica y Quirúrgica OMIQ & Head of Ophthalmology Department at Hospital Granollers said Clareon Vivity will broaden presbyopia correction offerings to more patients, including those with ocular comorbidities like glaucoma, age-related macular degeneration (AMD), or dry eyes.

Clareon Vivity’s broad range of dioptres and cylinders will help me address mild, moderate and high refractive error patients with a PCIOL,” said Dr. Guarro. “Clareon Vivity is an excellent lens option that improves vision with a visual disturbance profile of a monofocal IOL, giving my patients the freedom to engage in activities they love, both during the day and at night.”

“When we created Vivity, our goal was to develop an innovative lens that would minimize patients’ reliance on glasses and simplify presbyopia correction for surgeons, said Sunil Vasanth, Vice President Surgical Franchise, Europe. “We achieved this by designing a real EDOF lens, which has quickly become the world’s most implanted EDOF. This lens is now available in our most advanced biomaterial to date, Clareon.”

Yesterday, Alcon revealed it had begun an agreement to acquire Lensar, a maker of advanced systems for cataract treatment and management of astigmatism, for up to $430 million.